-
A Call for Improved Guidance to Integrate Modern Biomarkers Into Routine Clinical Care-Piecing the Puzzle Together. JAMA Oncol. (IF 22.5) Pub Date : 2025-02-06 Catherine Dunn,Jeanne Tie,Peter Gibbs
-
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer JAMA Oncol. (IF 22.5) Pub Date : 2025-02-06 Rebecca Kristeleit, Michael-John Devlin, Andrew Clamp, Charlie Gourley, René Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsell, Rowan E. Miller
ImportanceAdvanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with programmed cell death 1 protein (PD-1) inhibitors reported in CCGC merits further investigation.ObjectiveTo assess the clinical benefit of pembrolizumab in patients with previously treated advanced CCGC.Design, Setting, and
-
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma JAMA Oncol. (IF 22.5) Pub Date : 2025-02-06 Mark Roschewski, Dan L. Longo, James O. Armitage
ImportanceAchieving remission is the first step toward a cure in treating aggressive B-cell lymphomas. Radiographic imaging, such as fluorodeoxyglucose–positron emission tomography/computed tomography scans are the current standard to define remission at the end of therapy but lack specificity for lymphoma and cannot detect disease at the molecular level. Identifying measurable residual disease with
-
Concerns in Interpretation of Results In the Identification of Immune Checkpoint Inhibitor-Induced Diabetes-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-30 Karina N Ruiz-Esteves,Aaron J Deutsch,Michelle Rengarajan
-
Concerns in Interpretation of Results in the Identification of Immune Checkpoint Inhibitor-Induced Diabetes. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-30 Halis K Akturk,Aaron W Michels
-
Making Time—A Meta-Static Journey JAMA Oncol. (IF 22.5) Pub Date : 2025-01-30 Michael S. Avidan
This essay describes the author’s experience with an unexpected diagnosis of stage IV cancer and the valuable perspectives gained from unexpected additional quality time.
-
Urinary DNA Methylation Test for Bladder Cancer Diagnosis JAMA Oncol. (IF 22.5) Pub Date : 2025-01-30 In Gab Jeong, Sung-Cheol Yun, Hong Koo Ha, Sung Gu Kang, Sangchul Lee, Sungchan Park, Hyun Hwan Sung, Sun Il Kim, Eu Chang Hwang, Kyung Cheol Moon, Cheol Kwak
ImportanceAn accurate noninvasive biomarker test is needed for the early diagnosis of bladder cancer.ObjectiveTo evaluate the performance of a urinary DNA methylation test (PENK methylation) and compare its diagnostic accuracy with that of the nuclear matrix protein 22 (NMP22) test or urine cytology test.Design, Setting, and ParticipantsIn this prospective multicenter study at 10 sites in the Republic
-
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy JAMA Oncol. (IF 22.5) Pub Date : 2025-01-30 Sarah E. Lochrin, Hannah L. Kalvin, James W. Smithy, Monica F. Chen, Parisa Momtaz, Alexander N. Shoushtari, Katherine S. Panageas, Michael A. Postow
This cohort study examines the response and survival rates associated with ipilimumab-nivolumab therapy in patients with progressive melanoma brain metastases after anti–programmed cell death 1 (anti–PD-1) therapy.
-
Critical Review on Breast Cancer Research. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-23 Kwok Ying Chan,Chi Yan Wong
-
Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-23 Thomas F Stoop,Toshitaka Sugawara,Atsushi Oba,Isabel M Feld,Stijn van Roessel,Eran van Veldhuisen,Y H Andrew Wu,Jo Nishino,Mahsoem Ali,Adnan Alseidi,Alain Sauvanet,Antonello Mirabella,Antonio Sa Cunha,Arto Kokkola,Bas Groot Koerkamp,Daniel Pietrasz,Dyre Kleive,Giovanni Butturini,Giuseppe Malleo,Hanneke W M van Laarhoven,Isabella Frigerio,Jeanne Dembinski,Jin He,Johan Gagnière,Jörg Kleeff,Jose M Ramia
Importance The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy on overall survival (OS) is unclear because current studies do not account for the number of cycles of preoperative chemotherapy
-
New CMS Illness Navigation Codes: LinchPIN to Ensuring Better Access to Care? JAMA Oncol. (IF 22.5) Pub Date : 2025-01-23 John E Dobbs,Samyukta Mullangi,S M Qasim Hussaini
-
Critical Review on Breast Cancer Research-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-23 Julia S Wong,Hajime Uno,Rinaa S Punglia
-
Overcoming Barriers to Make Patient-Reported Outcome Collection the Standard of Care in Oncology. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-16 James A Colbert,Louis Potters
-
Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-16 Icro Meattini,Charlotte E Coles,Trine Tramm,Simona Borghesi,David Krug,Angel Montero,Valerio Nardone,Viola Salvestrini,Marianna Valzano,Vincenzo Valentini,Cynthia Aristei,Philip Poortmans,
Importance Integration of molecular biomarker information into systemic therapy has become standard practice in breast cancer care. However, its implementation in guiding radiotherapy (RT) is slower. Although postoperative RT is recommended for most patients after breast-conserving surgery and, depending on risk factors, following mastectomy, emerging evidence has indicated that patients with low scores
-
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ JAMA Oncol. (IF 22.5) Pub Date : 2025-01-16 Kirithiga Ramalingam, Rachel Woody, Alexa Glencer, Christopher J. Schwartz, Hidetoshi Mori, Jasmine Wong, Gillian Hirst, Jennifer Rosenbluth, Natsuko Onishi, Jessica Gibbs, Nola Hylton, Alexander D. Borowsky, Michael Campbell, Laura J. Esserman
ImportanceIntratumoral immunotherapy that leverages the biological characteristics of high-risk ductal carcinoma in situ (DCIS) may be able to reduce the extent of surgical treatment and provide an alternative approach to improve patient outcomes.ObjectiveTo determine if combination intratumoral immunotherapy can activate immune cells to shrink or eliminate high-risk DCIS.Design, Setting, and ParticipantsThis
-
Gastroenteropancreatic Neuroendocrine Tumor Incidence by Sex and Age in the US JAMA Oncol. (IF 22.5) Pub Date : 2025-01-16 Yazan Abboud, Anand Shah, Riya Sutariya, Vraj P. Shah, Ahmed Al-Khazraji, Paul J. Gaglio, Kaveh Hajifathalian
This observational study reports on a comprehensive nationwide evaluation of rising gastroenteropancreatic neuroendocrine tumor incidence in the US from 2001 to 2020.
-
Uncertain Prognostic Impact of Visceral Pleural Invasion-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-09 Nasser Altorki,Xiaofei Wang,Thomas E Stinchcombe
-
Weight Changes and Heart Failure Risk After Breast Cancer Development. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-09 Wonyoung Jung,Yong-Moon Mark Park,Jonghan Yu,Jung Eun Yoo,In Young Cho,Kyungdo Han,Dong Wook Shin
-
Uncertain Prognostic Impact of Visceral Pleural Invasion. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-09 Bahadir Köylü,Deniz Can Güven
-
What We Can Learn About Patient Safety While Driving to Work JAMA Oncol. (IF 22.5) Pub Date : 2025-01-09 Lawrence B. Marks, Caprice C. Greenberg, Lukasz M. Mazur
This Viewpoint discusses strategies used with driving that can be applied to health care to promote consistent and predictable physician and patient actions.
-
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies JAMA Oncol. (IF 22.5) Pub Date : 2025-01-09 Kanika Arora, Sarah P. Suehnholz, Hongxin Zhang, Irina Ostrovnaya, Ritika Kundra, Subhiksha Nandakumar, Moriah H. Nissan, A. Rose Brannon, Chaitanya Bandlamudi, Marc Ladanyi, Alexander Drilon, Carol L. Brown, David B. Solit, Nikolaus Schultz, Michael F. Berger, Debyani Chakravarty
ImportanceAlthough differences in the prevalence of key cancer-specific somatic mutations as a function of genetic ancestry among patients with cancer has been well-established, few studies have addressed the practical clinical implications of these differences for the growing number of biomarker-driven treatments.ObjectiveTo determine if the approval of precision oncology therapies has benefited patients
-
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation JAMA Oncol. (IF 22.5) Pub Date : 2025-01-09 Gregory A. Abel, Haesook T. Kim, Ira Zackon, Edwin T. Alyea, Alexandra S. Bailey, John P. Winters, Kenneth R. Meehan, John L. Reagan, Jeanna H. Walsh, Thomas P. Walsh, Alexandra Ivanov, Meredith A. Faggen, Sarah Sinclair, Amy C. Joyce, Sara D. Close, Amy Emmert, Jon Koreth, Joseph H. Antin, Corey S. Cutler, Vincent T. Ho, Robert J. Soiffer
ImportanceAlthough sharing care with local oncologists after allogeneic hematopoietic cell transplantation (HCT) has been proposed for patients living far from HCT centers, it is not known whether a shared strategy is safe or improves patient quality of life (QOL).ObjectiveTo determine the efficacy and safety of sharing follow-up care after HCT between the HCT specialty center and local oncologists
-
Nontransplant Treatment for Relapsed Pediatric Hodgkin Lymphoma-Less Is More. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-02 Ilia N Buhtoiarov,Rabi Hanna
-
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults JAMA Oncol. (IF 22.5) Pub Date : 2025-01-02 Stephen Daw, Peter D. Cole, Bradford S. Hoppe, David Hodgson, Auke Beishuizen, Nathalie Garnier, Salvatore Buffardi, Maurizio Mascarin, Andrej Lissat, Christine Mauz-Körholz, Jennifer Krajewski, Alev Akyol, Russell Crowe, Bailey Anderson, Yan Xu, Richard A. Drachtman, Kara M. Kelly, Thierry Leblanc, Paul Harker-Murray
ImportanceRetrieval strategies for children, adolescents, and young adults with relapsed classic Hodgkin lymphoma (cHL) aim to maintain efficacy while minimizing long-term toxic effects. Children, adolescents, and young adults with low-risk, relapsed cHL may benefit from replacing high-dose chemotherapy and autologous stem cell transplant with less intensive involved-site radiotherapy (ISRT).ObjectiveTo
-
Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma JAMA Oncol. (IF 22.5) Pub Date : 2025-01-02 Bradford S. Hoppe, Sarah A. Milgrom, Lindsay A. Renfro, Yue Wu, Cindy L. Schwartz, Louis S. Constine, Kathleen M. McCarten, Kara M. Kelly, David Hodgson, Sharon M. Castellino, Frank G. Keller
This nonrandomized clinical trial reports outcomes for children with low-risk relapsed Hodgkin lymphoma treated with second-line chemotherapy and involved-field radiotherapy without autologous stem cell transplant.
-
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma JAMA Oncol. (IF 22.5) Pub Date : 2025-01-02 Stephen Daw, Alexander Claviez, Lars Kurch, Dietrich Stoevesandt, Andishe Attarbaschi, Walentyna Balwierz, Auke Beishuizen, Michaela Cepelova, Francesco Ceppi, Ana Fernandez-Teijeiro, Alexander Fosså, Thomas W. Georgi, Lisa Lyngsie Hjalgrim, Andrea Hraskova, Thierry Leblanc, Maurizio Mascarin, Jane Pears, Judith Landman-Parker, Tomaž Prelog, Wolfram Klapper, Alan Ramsay, Regine Kluge, Karin Dieckmann
ImportanceThe current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT).ObjectiveTo investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between
-
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-26 Manuel David Gil-Sierra,María Del Pilar Briceño-Casado,Cristina Moreno-Ramos
-
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-12-26 Mehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, Joao V. Alessi, Alessio Cortellini, Fabrizio Citarella, Lorenzo Nibid, Giuseppe Perrone, Elio Adib, Claudia A. M. Fulgenzi, Cassio Murilo Hidalgo Filho, Alessandro Di Federico, Falah Jabar, Sayed Hashemi, Ilias Houda, Elin Richardsen, Lill-Tove Rasmussen Busund, Tom Donnem, Idris Bahce, David J. Pinato, Åslaug Helland, Lynette M. Sholl, Mark M. Awad
ImportanceOnly a small fraction of patients with advanced non−small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to identify patients who are most likely to benefit from immunotherapy.ObjectiveTo develop a supervised deep learning−based ICI response prediction method; evaluate its performance alongside other known
-
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy JAMA Oncol. (IF 22.5) Pub Date : 2024-12-26 Jonas Saal, Markus Eckstein, Manuel Ritter, Peter Brossart, Julian Luetkens, Jörg Ellinger, Viktor Grünwald, Michael Hölzel, Niklas Klümper
ImportanceProgressive disease (PD) in patients treated with immune checkpoint inhibitors (ICIs) varies widely in outcomes according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Efforts to modify RECIST for ICI treatment have not resolved the heterogeneity in PD patterns, posing a clinical challenge.ObjectiveTo develop and validate a modified PD classification based on
-
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors JAMA Oncol. (IF 22.5) Pub Date : 2024-12-26 Craig Horbinski, David A. Solomon, Rimas V. Lukas, Roger J. Packer, Priscilla Brastianos, Patrick Y. Wen, Matija Snuderl, Mitchel S. Berger, Susan Chang, Maryam Fouladi, Joanna J. Phillips, Burt Nabors, Daniel J. Brat, Jason T. Huse, Kenneth Aldape, Jann N. Sarkaria, Matthias Holdhoff, Terry C. Burns, Katherine B. Peters, Ingo K. Mellinghoff, David Arons, Evanthia Galanis
ImportanceMolecular techniques, including next-generation sequencing, genomic copy number profiling, fusion transcript detection, and genomic DNA methylation arrays, are now indispensable tools for the workup of central nervous system (CNS) tumors. Yet there remains a great deal of heterogeneity in using such biomarker testing across institutions and hospital systems. This is in large part because
-
Government Funding for the Development of Enzalutamide JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Bishal Gyawali, Emily H. Jung, Helen Mooney, Jerry Avorn, Aaron S. Kesselheim
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
-
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Laura A. Dawson, Kathryn A. Winter, Jennifer J. Knox, Andrew X. Zhu, Sunil Krishnan, Chandan Guha, Lisa A. Kachnic, Michael T. Gillin, Theodore S. Hong, Timothy D. Craig, Terence M. Williams, Ali Hosni, Eric Chen, Anne M. Noonan, Eugene J. Koay, Rishi Sinha, Michael I. Lock, Nitin Ohri, Jennifer A. Dorth, Guila Delouya, Anand Swaminath, Jennifer Moughan, Christopher H. Crane
ImportanceMost patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy.ObjectiveTo determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.Design, Setting, and ParticipantsThis multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1
-
Assessing the Risk of Radiation Myelitis in Hypofractionated Stereotactic Body Radiation Therapy-Tolerance Is in the Eye of the Beholder. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Evangelia Katsoulakis,Daniel E Spratt
-
Radiation Myelitis Risk After Hypofractionated Spine Stereotactic Body Radiation Therapy JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Christopher B. Jackson, Lillian A. Boe, Lei Zhang, Aditya Apte, Lisa M. Ruppert, Justin M. Haseltine, Boris A. Mueller, Adam M. Schmitt, Jonathan T. Yang, W. Christopher Newman, Ori Barzilai, Mark H. Bilsky, Yoshiya Yamada, Andrew Jackson, Eric Lis, Daniel S. Higginson
ImportanceStereotactic body radiation therapy (SBRT) for spinal metastases improves symptomatic outcomes and local control compared to conventional radiotherapy. Treatment failure most often occurs within the epidural space, where dose is constrained by the risk of radiation myelitis (RM). Current constraints designed to prevent RM after spine SBRT are derived from limited data.ObjectiveTo characterize
-
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Charlie A. Hamm, Patrick Asbach, Anna Pöhlmann, Ivo G. Schoots, Veeru Kasivisvanathan, Thomas O. Henkel, Manfred Johannsen, Thomas Speck, Alexander D. J. Baur, Matthias Haas, Federico Collettini, Tobias Penzkofer, Lynn J. Savic, Frank Konietschke, Lothar Weißbach, Bernd Hamm, Frank König, Hannes Cash
ImportanceThe magnetic resonance imaging (MRI) pathway for diagnosing clinically significant prostate cancer (csPCa; defined as International Society of Urological Pathology grade group ≥2) uses multiparametric MRI (mpMRI) for prostate biopsy (PB) decision-making. However, the intermediate impact on patient outcomes in men with negative MRI results avoiding PB and men with positive MRI results without
-
Polygenic Risk Scores for Prostate Cancer: Informing Prevention or Therapy. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Konrad H Stopsack
-
Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Louisa B. Goss, Menghan Liu, Yingye Zheng, Boya Guo, David V. Conti, Christopher A. Haiman, Linda Kachuri, William J. Catalona, John S. Witte, Daniel W. Lin, Lisa F. Newcomb, Burcu F. Darst
ImportanceActive surveillance is the preferred management strategy for patients with low- or favorable intermediate-risk prostate cancer (PCa); however, frequent health care visits can be costly and burdensome to patients. Identifying patients who may benefit from intensive vs passive surveillance could reduce these burdens.ObjectiveTo investigate associations between a polygenic risk score (PRS) and
-
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Steven A Narod,Vasily Giannakeas
-
Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Thomas J O'Keefe,Michael D Alvarado,Laura J Esserman
-
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Shyam A. Patel, Jay Y. Spiegel, Saurabh Dahiya
ImportanceThe commercialization of chimeric antigen receptor–T-cell (CAR-T) therapy has changed the landscape of treatment of hematological cancers. Numerous studies from the early 2000s paved the way for cell-based targeted therapeutics, which have been established as practice-changing therapies in lymphoma, leukemia, and multiple myeloma. However, there has been some recent concern about the risk
-
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-12 Ann H Partridge,Terry Hyslop,Shoshana M Rosenberg,Antonia V Bennett,Sarah Drier,Mattias Jonsson,Ayako Shimada,Yutong Li,Yan Li,Thomas Lynch,Elizabeth Frank,Deborah Collyar,Desiree Basila,Donna Pinto,Anna Weiss,Anna Wolf,Kelsey Norris,Meredith Witten,Marc Boisvert,Armando Giuliano,Kelsey E Larson,Kathleen Yost,Priscilla F McAuliffe,Amy Krie,Nina Tamirisa,Sonja Darai,Lisa Carey,Alastair Thompson,E Shelley
Importance Active monitoring (AM) for low-risk ductal carcinoma in situ (DCIS) has been considered as a potential alternative to guideline-concordant care (GCC; inclusive of surgery with or without radiation). Reported data comparing patient-reported outcomes (PROs) between GCC and AM for DCIS are lacking. Objective To compare PROs at baseline and over time in patients with low-risk DCIS randomized
-
Neoadjuvant Exercise Therapy in Patients With Prostate Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 Lee W Jones,Behfar Ehdaie,Paul C Boutros
-
Neoadjuvant Exercise Therapy in Patients With Prostate Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 Fabian Falkenbach,Lars Budäus
-
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 Hyo S. Han, Amy L. Aldrich, Saurabh K. Garg, R. Jared Weinfurtner, Jonathan V. Nguyen, Qianxing Mo, Junmin Whiting, Jennifer Childress, Hatem Soliman, Ricardo Costa, Avan Armaghani, Aixa Soyano, John Kiluk, Susan Hoover, Marie C. Lee, Nazanin Khakpour, Nithin Shenoi, Zena Jameel, Gary K. Koski, Brian J. Czerniecki
ImportanceCurrent chemotherapy regimens for patients with ERBB2 (formerly HER2)–positive breast cancer are associated with considerable morbidity. These patients may benefit from more effective and less toxic therapies.ObjectiveTo evaluate the safety, immunogenicity, and preliminary efficacy of intratumoral (IT) delivery of conventional type 1 dendritic cells (cDC1) in combination with ERBB2-targeted
-
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020 JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 Katrina A. B. Goddard, Eric J. Feuer, Jeanne S. Mandelblatt, Rafael Meza, Theodore R. Holford, Jihyoun Jeon, Iris Lansdorp-Vogelaar, Roman Gulati, Natasha K. Stout, Nadia Howlader, Amy B. Knudsen, Daniel Miller, Jennifer L. Caswell-Jin, Clyde B. Schechter, Ruth Etzioni, Amy Trentham-Dietz, Allison W. Kurian, Sylvia K. Plevritis, John M. Hampton, Sarah Stein, Liyang P. Sun, Asad Umar, Philip E. Castle
ImportanceCancer mortality has decreased over time, but the contributions of different interventions across the cancer control continuum to averting cancer deaths have not been systematically evaluated across major cancer sites.ObjectiveTo quantify the contributions of prevention, screening (to remove precursors [interception] or early detection), and treatment to cumulative number of cancer deaths
-
A Values Proposition for Cancer Care JAMA Oncol. (IF 22.5) Pub Date : 2024-12-05 William E. Rosa, Andrew S. Epstein, Judith E. Nelson
This Viewpoint discusses what a value proposition could look like in oncology and how it should reflect a clinician’s commitment to partner with patients to improve outcomes through individualized communication and shared decision-making centered on the patient’s values.
-
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Amanda L Blackford,Marcia Irene Canto,Michael Goggins
-
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Christopher Dasaro,Vinay Prasad
-
Colorectal Cancer Incidence and Mortality After Negative Colonoscopy Screening Results JAMA Oncol. (IF 22.5) Pub Date : 2024-11-27 Markus Dines Knudsen, Kai Wang, Liang Wang, Georgios Polychronidis, Paula Berstad, Anette Hjartåker, Zhe Fang, Shuji Ogino, Andrew T. Chan, Mingyang Song
ImportanceThe current recommendation for a 10-year rescreening interval after a negative colonoscopy screening (NCS) result has been questioned, with some studies showing a persistently lower risk of colorectal cancer (CRC) after NCS results.ObjectiveTo examine long-term CRC incidence and mortality after NCS results (ie, no presence of CRC or polyps) and according to a risk score based on major demographic
-
Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies JAMA Oncol. (IF 22.5) Pub Date : 2024-11-27 Michael V. Gormally, Monica F. Chen, Anne Marie Noronha, Kristalla Panageas, Maggie Reynolds, Kaelyn Kohlasch, Bryan Novak, Tatiana Kee-Velez, Nikeysha Clarke, Michael Eubank, Cynthia Chu, Clare Wilhelm, Amanda Blouin, Chrisann Kyi, Claire Friedman, Charles M. Rudin, Mark G. Kris, Ronak Shah, David Aggen, Sandra D’Angelo, Alexander N. Shoushtari, Michael F. Berger, Chaitanya Bandlamudi, Christopher
This case series evaluates whether human leukocyte antigen (HLA) genotype could be inferred from standard next-generation sequencing, comparing concordance with confirmatory whole-exome sequencing and assessing if this assisted in matching patients to clinical trials.
-
Targeting CNS Metastases in Non–Small Cell Lung Cancer With Evolving Approaches Using Molecular Markers JAMA Oncol. (IF 22.5) Pub Date : 2024-11-27 Jyoti Malhotra, Isa Mambetsariev, Gregory Gilmore, Jeremy Fricke, Arin Nam, Natalie Gallego, Bihong T. Chen, Mike Chen, Arya Amini, Rimas V. Lukas, Ravi Salgia
ImportanceCentral nervous system (CNS) metastases presenting as either brain parenchymal metastases or leptomeningeal metastases are diagnosed in up to 50% of patients with advanced non–small cell lung cancer during their disease course. While historically associated with a poor prognosis due to limited treatment options, the availability of an increasing number of targeted therapies with good CNS
-
FOLFOX/FOLFIRI-Bevacizumab for Unresectable Colorectal Liver Metastases. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Jan Franko,Viet H Le
-
More on Waterpipe Tobacco Smoking and Cancer Mortality Content. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Ping-Hao Chiang,Chieh-Hsuan Tsai
-
More on Waterpipe Tobacco Smoking and Cancer Mortality Content -Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Ngoan Tran Le,Jian-Min Yuan,Hung N Luu
-
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Marinde J G Bond,Karen Bolhuis,Olaf J L Loosveld,Jan Willem B de Groot,Helga Droogendijk,Helgi H Helgason,Mathijs P Hendriks,Joost M Klaase,Geert Kazemier,Mike S L Liem,Arjen M Rijken,Cornelis Verhoef,Johannes H W de Wilt,Koert P de Jong,Michael F Gerhards,Martinus J van Amerongen,Marc R W Engelbrecht,Krijn P van Lienden,John J Hermans,I Quintus Molenaar,Dirk J Grünhagen,Bart de Valk,Brigitte C M Haberkorn
Importance In patients with colorectal cancer and unresectable liver-only metastases (CRLM), treatment with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus irinotecan (FOLFOXIRI) and bevacizumab vs FOLFOX/folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus bevacizumab increased progression-free survival, response, and R0/R1 resection/ablation rates, as well as toxic effects in RAS/BRAFV600E-variant
-
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib JAMA Oncol. (IF 22.5) Pub Date : 2024-11-21 Elias Jabbour, Vivian G. Oehler, Paul B. Koller, Omer Jamy, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Jorge E. Cortes, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Huanshan Guo, Zi Chen, Tommy Fu, Lixin Jiang, Cunlin Wang, Hengbang Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian
ImportancePatients with chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) resistant or intolerant to BCR-ABL1 tyrosine kinase inhibitors (TKIs) have limited treatment options. Olverembatinib, which is approved in China, has only been tested in Chinese patients.ObjectiveTo assess the pharmacokinetics, safety, efficacy, and recommended dose of olverembatinib
-
A SEER Registry–Based Analysis of Pediatric Colorectal Adenocarcinomas JAMA Oncol. (IF 22.5) Pub Date : 2024-11-21 Sameh Hany Emile, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Justin Dourado, Steven D. Wexner
This cohort study analyzes the characteristics of colorectal cancer in pediatric patients using Surveillance, Epidemiology, and End Results (SEER) registry data.
-
Toripalimab for Extensive-Stage Small Cell Lung Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Ayse Ece Cali Daylan,Daniel Morgensztern,Saiama N Waqar
-
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Xiaoling Xu,Lisha Ye,Yaping Xu
-
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2025-01-01 Song Dong,Hong-Hong Yan,Yi-Long Wu